Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseActive, not recruitingPhase 22026-09-25NCT06577025

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Janssen Research & Development, LLC188

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
City of HopeDuarteUnited States238
Fundacao Antonio Prudente A C Camargo Cancer CenterSão PauloBrazil23
Hosp Clinico Univ de SalamancaSalamancaSpain34
Hosp. Univ. 12 de OctubreMadridSpain68
Hosp. Univ. Marques de ValdecillaSantanderSpain30
IDOR - Regional BahiaSalvadorBrazil15
Levine Cancer InstituteCharlotteUnited States110
Memorial Sloan Kettering Cancer CenterNew YorkUnited States1000
Peter MacCallum Cancer CentreMelbourneAustralia32
Sociedade Beneficente Israelita Brasileira Hospital Albert EinsteinSão PauloBrazil8
The Alfred HospitalMelbourneAustralia26
Universitaetsklinikum HeidelbergHeidelbergGermany48
Universitaetsklinikum TuebingenTübingenGermany29
Universitatsklinikum WurzburgWürzburgGermany19
University of California San FranciscoSan FranciscoUnited States144
University of Iowa Hospital and ClinicsIowa CityUnited States30